These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12088199)

  • 1. Oral contraceptives and risk of familial breast cancer.
    Heimdal K; Skovlund E; Møller P
    Cancer Detect Prev; 2002; 26(1):23-7. PubMed ID: 12088199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral contraceptives and breast cancer risk in Taiwan, a country of low incidence of breast cancer and low use of oral contraceptives.
    Chie WC; Li CY; Huang CS; Chang KJ; Yen ML; Lin RS
    Int J Cancer; 1998 Jul; 77(2):219-23. PubMed ID: 9650556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Narod SA; Dubé MP; Klijn J; Lubinski J; Lynch HT; Ghadirian P; Provencher D; Heimdal K; Moller P; Robson M; Offit K; Isaacs C; Weber B; Friedman E; Gershoni-Baruch R; Rennert G; Pasini B; Wagner T; Daly M; Garber JE; Neuhausen SL; Ainsworth P; Olsson H; Evans G; Osborne M; Couch F; Foulkes WD; Warner E; Kim-Sing C; Olopade O; Tung N; Saal HM; Weitzel J; Merajver S; Gauthier-Villars M; Jernstrom H; Sun P; Brunet JS
    J Natl Cancer Inst; 2002 Dec; 94(23):1773-9. PubMed ID: 12464649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing.
    Jernström H; Loman N; Johannsson OT; Borg A; Olsson H
    Eur J Cancer; 2005 Oct; 41(15):2312-20. PubMed ID: 16118051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.
    Haile RW; Thomas DC; McGuire V; Felberg A; John EM; Milne RL; Hopper JL; Jenkins MA; Levine AJ; Daly MM; Buys SS; Senie RT; Andrulis IL; Knight JA; Godwin AK; Southey M; McCredie MR; Giles GG; Andrews L; Tucker K; Miron A; Apicella C; Tesoriero A; Bane A; Pike MC; ; ; Whittemore AS
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1863-70. PubMed ID: 17021353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
    Jernström H; Sandberg T; Bågeman E; Borg A; Olsson H
    Int J Gynecol Cancer; 2006; 16 Suppl 2():497. PubMed ID: 17010055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.
    Figueiredo JC; Haile RW; Bernstein L; Malone KE; Largent J; Langholz B; Lynch CF; Bertelsen L; Capanu M; Concannon P; Borg A; Børresen-Dale AL; Diep A; Teraoka S; Torngren T; Xue S; Bernstein JL
    Breast Cancer Res Treat; 2010 Feb; 120(1):175-83. PubMed ID: 19597986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?
    Ursin G; Henderson BE; Haile RW; Pike MC; Zhou N; Diep A; Bernstein L
    Cancer Res; 1997 Sep; 57(17):3678-81. PubMed ID: 9288771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers.
    Kotsopoulos J; Lubinski J; Moller P; Lynch HT; Singer CF; Eng C; Neuhausen SL; Karlan B; Kim-Sing C; Huzarski T; Gronwald J; McCuaig J; Senter L; Tung N; Ghadirian P; Eisen A; Gilchrist D; Blum JL; Zakalik D; Pal T; Sun P; Narod SA;
    Breast Cancer Res Treat; 2014 Feb; 143(3):579-86. PubMed ID: 24458845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer among young U.S. women in relation to oral contraceptive use.
    White E; Malone KE; Weiss NS; Daling JR
    J Natl Cancer Inst; 1994 Apr; 86(7):505-14. PubMed ID: 8133534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
    Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
    Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
    Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.
    Moorman PG; Havrilesky LJ; Gierisch JM; Coeytaux RR; Lowery WJ; Peragallo Urrutia R; Dinan M; McBroom AJ; Hasselblad V; Sanders GD; Myers ER
    J Clin Oncol; 2013 Nov; 31(33):4188-98. PubMed ID: 24145348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women.
    Gammon MD; Hibshoosh H; Terry MB; Bose S; Schoenberg JB; Brinton LA; Bernstein JL; Thompson WD
    Cancer Epidemiol Biomarkers Prev; 1999 May; 8(5):413-9. PubMed ID: 10350436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden.
    Olsson H; Möller TR; Ranstam J
    J Natl Cancer Inst; 1989 Jul; 81(13):1000-4. PubMed ID: 2733043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weighing the evidence on the pill and breast cancer.
    Johnson JH
    Fam Plann Perspect; 1989; 21(2):89-92. PubMed ID: 2653859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral contraceptive use and BRCA penetrance: a case-only study.
    Pasanisi P; Hédelin G; Berrino J; Chang-Claude J; Hermann S; Steel M; Haites N; Hart J; Peled R; Gafà L; Leggio L; Traina A; Amodio R; Primic-Zakelj M; Zadnik V; Veidebaum T; Tekkel M; Berrino F
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2107-13. PubMed ID: 19549808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral contraceptive use and breast cancer in young women. A joint national case-control study in Sweden and Norway.
    Meirik O; Lund E; Adami HO; Bergström R; Christoffersen T; Bergsjö P
    Lancet; 1986 Sep; 2(8508):650-4. PubMed ID: 2876135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.
    Grabrick DM; Hartmann LC; Cerhan JR; Vierkant RA; Therneau TM; Vachon CM; Olson JE; Couch FJ; Anderson KE; Pankratz VS; Sellers TA
    JAMA; 2000 Oct; 284(14):1791-8. PubMed ID: 11025831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.